A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers

Cancer(s): Lung, Pancreatic, Colorectal
Study Phase: phase 1
Status: recruiting
Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
ClinicalTrials.gov Identifier: NCT06917079
Disease Focus: Non-Small Cell Lung Cancer
Principal Investigator: Jun Zhang, MD, PhD
Clinical Research Coordinator: Jennifer Dixon

Study Overview

A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

clinicaltrials.gov NCT:NCT06917079

Interested in Participating in this Trial?

If you are interested in participating in this study, call the OSF Hope line at (844) 673- 4467 or email: sfmc.clinicaltrials@osfhealthcare.org